Research programme: fixed combination respiratory tract disorder therapeutics - Circassia Pharmaceuticals

Drug Profile

Research programme: fixed combination respiratory tract disorder therapeutics - Circassia Pharmaceuticals

Alternative Names: PSX 2000 MCP Series; PSX 3000 MCPTM Series; PSX MCP™ Series

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Prosonix
  • Developer Circassia; Imperial College of Science, Technology and Medicine
  • Class Androstadienes; Ethanolamines; Phenethylamines; Pregnenediones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Asthma; Chronic obstructive pulmonary disease; Respiratory tract disorders

Most Recent Events

  • 07 Nov 2014 Development is ongoing in United Kingdom
  • 05 Jul 2012 Early research in Asthma in United Kingdom (Inhalation)
  • 05 Jul 2012 Early research in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top